Congress contribution in 2020

SABCS: San Antonio Breast Cancer Symposium, December 8-11, 2020, Virtual Meeting

  • Loibl S, Marmé F, Martin M, et al. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B. SABCS 2020, Abstract GS1-02.
  • Sestak I, Cuzick J, Bonanni B, et al. 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. SABCS 2020, Abstract GS2-02.
    Krop I, Mittempergher L, Paulson J, et al. BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial. SABCS 2020, Abstract PD3-01.
  • Ciruelos EM, Loibl S, Mayer IA, et al. Clinical Outcomes of Alpelisib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer With PIK3CA Alterations Detected in Plasma ctDNA by Next-Generation Sequencing: Biomarker Analysis From the SOLAR-1 Study. SABCS 2020, Abstract PD2-06.
  • Mayer EL, Fesl C, Dueck A et al. Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer. SABCS 2020, Abstract PD2-03.
  • Franzoi MA, Procter M, Emond O, et al. Timelines to initiate an adjuvant phase III trial across the globe: a sub-analysis of the APHINITY trial. SABCS 2020, Abstract PS7-21.
  • Gelber RD, Wang XV, Cole BF, et al. 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a STEPP analysis of the APHINITY (BIG 4-11) trial. SABCS 2020, Abstract PS10-01.
  • Núria N, Luen SJ, Nuciforo P, et al. CelTIL score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial. SABCS 2020, Abstract PS5-03.
  • Mayer I, Farooki A, Rugo HS, et al. Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: case studies from the Phase III SOLAR-1 trial. SABCS 2020, Abstract PS10-35.
  • Rugo HS, Tolaney SM, Loirat D, et al. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients (pts) with metastatic triple-negative breast cancer (mTNBC). SABCS 2020, Abstract PS11-09.
  • Geyer, Jr CE, Untch M, Prat A, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05). SABCS 2020, Abstract OT-03-01.

DGGG: 63. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2020, October 7-9, 2020, Virtual Meeting

  • Riecke K, Müller V, Neunhöffer T, et al. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. oral presentation.

EBCC: European Breast Cancer Conference 2020, October 2-3, 2020, Virtual Meeting

  • Nuciforo P, Townend J, Saura C et al. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. Eur J Cancer 2020; Vol 138, S15-S16, oral presentation.
  • Rugo H, Cristofanilli M, Loibl S, et al. Predictors of efficacy in patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3. Eur J Cancer 2020; Vol 138, S7-S8, oral presentation.
  • Laakmann E, Witzel I, Neunhöffer T, et al. Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases. Eur J Cancer 2020; Vol 138, S19, poster.

ESMO: European Society for Medical Oncology, September 19-21, 2020, Virtual Meeting

  • Schneeweiss A, Möbus V, Tesch H, et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Ann Oncol 2020; Vol. 31, Suppl.4, S303-S304, oral presentation.
  • Mayer EL, Gnant MI, DeMichele A, et al. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Ann Oncol 2020; Vol. 31, Suppl.4, S1145, oral presentation (proffered paper).
  • André F, Ciruelos EM, Juric D, et al. Overall Survival (OS) Results From SOLAR-1, a Phase 3 Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC). Ann Oncol 2020; Vol. 31, Suppl.4, S1142-S1215, oral presentation.
    Link T, Blohmer J-U, Just M, et al. GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann Oncol 2020; Vol. 31, Suppl.4, S308-S309, minioral presentation.
  • Hauke J, Ernst C, Fasching PA, et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann Oncol 2020; Vol. 31, Suppl.4, S313, poster.
  • Rugo HS, Cristofanilli M, Loibl S, et al. Prognostic Factors for Overall Survival in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Analyses From PALOMA-3. Ann Oncol 2020; Vol. 31, Suppl.4, S372-S373, poster.
  • Loibl S, Rastogi P, Seiler S, et al. A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze). Ann Oncol 2020; Vol. 31, Suppl.4, S339, TIP.

AACR: American Association for Cancer Research, Annual Meeting June 22-24, 2020, Virtual Meeting

  • Benelli M, Biagioni C, Fimereli D, et al. Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. Cancer Res 2020;80(16 Suppl):Abstract nr 2488, poster.

ASCO: American Society of Clinical Oncology, Annual Meeting May 29-30, 2020, Virtual Meeting

  • Denkert C, Lambertini C, Fasching PA, et al. Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. J Clin Oncol.2020; 38.15_suppl.502, oral presentation.
  • Moebus V, Lueck HJ, Ladda E, et al. GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS). J Clin Oncol.2020; 38.15_suppl.516, poster discussion.
  • Rediti M, Venet D, Rothe F, et al. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. J Clin Oncol. 2020; 38.15_suppl.511, poster discussion.
    Cui W, Francis PA, Loi S, et al. Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review. J Clin Oncol.2020; 38. 15_suppl. e14098, session publication only.
  • Wimberger P, Blohmer J-U, Krabisch P, et al. Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy. J Clin Oncol.2020; 38.15_suppl.580, poster.
  • Kolberg HC, Kühn T, Krajewska M, et al. Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis. J Clin Oncol.2020; 38.15_suppl.557, poster.

ESMO-Breast Cancer May 23-24, 2020, Virtual Meeting

  • Loibl S, Huang CS, Mano MS, et al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE. Ann Oncol. 2020; Vol 31, S48, oral presentation.
  • Karn T, Denkert C, Weber K, et al. Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020, Vol. 31, S58, oral presentation.
  • Curigliano G, Murthy R, Loi R, et al. Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Ann Oncol 2020; Vol. 31, Suppl.4, S62-S63, oral presentation.
  • Reinisch M, Untch M, Reimer T, et al. Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Ann Oncol 2020, Vol. 31, S44, poster.
  • Riecke K, Mueller V, Neunhöffer T, et al. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores. Ann Oncol 2020, Vol. 31, S70, poster.

DKK: 34. Deutsche Krebskongress 2020, February 19-22, 2020, Berlin Germany

  • Furlanetto J, Nekljudova V, Schneeweiss A, et al. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). DKK 2020, oral presentation.
  • Furlanetto J, Möbus V, Schneeweiss A, et al. Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT). DKK 2020, poster.
  • Pohl-Rescigno E, Hauke J, Rhiem K, et al. Germline mutation status and therapy response in high-risk early-stage breast cancer: A secondary analysis of the GeparOcto randomized clinical trial (NCT02125344). DKK 2020, poster.
  • Tesch H, Loibl S, Kast K, et al. Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study. DKK 2020, poster.
  • Seiler S, Schmatloch S, Reinisch M, et al. Cancer Management and Outcome of young patients (pts) with breast cancer (BC) diagnosed at 40 years (yrs) or younger. DKK 2020, poster.
  • Loibl S, Jackisch C, Seiler S, et al. Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with Atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of Atezolizumab/Placebo (GeparDouze). DKK 2020, TIP.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd